SK13252002A3 - Farmaceutické prípravky - Google Patents

Farmaceutické prípravky Download PDF

Info

Publication number: SK13252002A3
Authority: SK; Slovakia
Prior art keywords: fatty acid; pharmaceutical preparations; acid esters; preparations according; sucrose
Prior art date: 2000-03-08

Application number

SK1325-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Torsten Hoffmann

Michael Pieroth

Gerhard Zessin

Karl-Friedrich Landgraf

Original Assignee

Awd. Pharma Gmbh & Co. Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-08

Filing date

2001-03-06

Publication date

2003-07-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26004678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK13252002(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-03-08 Priority claimed from DE2000110509 external-priority patent/DE10010509A1/de

2001-03-06 Application filed by Awd. Pharma Gmbh & Co. Kg filed Critical Awd. Pharma Gmbh & Co. Kg

2003-07-01 Publication of SK13252002A3 publication Critical patent/SK13252002A3/sk

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims description 34
-1 sucrose fatty acid esters Chemical class 0.000 claims abstract description 89
229930006000 Sucrose Natural products 0.000 claims abstract description 83
239000005720 sucrose Substances 0.000 claims abstract description 83
235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 79
239000000194 fatty acid Substances 0.000 claims abstract description 79
229930195729 fatty acid Natural products 0.000 claims abstract description 79
238000000034 method Methods 0.000 claims abstract description 54
238000004519 manufacturing process Methods 0.000 claims abstract description 33
239000000203 mixture Substances 0.000 claims abstract description 27
239000004480 active ingredient Substances 0.000 claims abstract description 25
239000003795 chemical substances by application Substances 0.000 claims abstract description 14
238000005453 pelletization Methods 0.000 claims abstract description 9
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
239000008203 oral pharmaceutical composition Substances 0.000 claims abstract description 5
239000013543 active substance Substances 0.000 claims description 71
239000008187 granular material Substances 0.000 claims description 49
230000008569 process Effects 0.000 claims description 35
239000000126 substance Substances 0.000 claims description 35
PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims description 31
229960003312 retigabine Drugs 0.000 claims description 31
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 24
238000002844 melting Methods 0.000 claims description 18
230000008018 melting Effects 0.000 claims description 18
239000000546 pharmaceutical excipient Substances 0.000 claims description 16
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 15
229960000623 carbamazepine Drugs 0.000 claims description 15
238000000576 coating method Methods 0.000 claims description 15
238000007909 melt granulation Methods 0.000 claims description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
239000002552 dosage form Substances 0.000 claims description 14
229940095670 calcium valproate Drugs 0.000 claims description 13
239000011230 binding agent Substances 0.000 claims description 11
239000011248 coating agent Substances 0.000 claims description 11
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 11
229960001597 nifedipine Drugs 0.000 claims description 11
238000003756 stirring Methods 0.000 claims description 10
239000008188 pellet Substances 0.000 claims description 9
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 7
239000001069 triethyl citrate Substances 0.000 claims description 7
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 7
235000013769 triethyl citrate Nutrition 0.000 claims description 7
239000004014 plasticizer Substances 0.000 claims description 6
239000007858 starting material Substances 0.000 claims description 6
PIZHURYFCSGTJX-UHFFFAOYSA-L calcium;2-propylpentanoate Chemical compound [Ca+2].CCCC(C([O-])=O)CCC.CCCC(C([O-])=O)CCC PIZHURYFCSGTJX-UHFFFAOYSA-L 0.000 claims description 5
238000007757 hot melt coating Methods 0.000 claims description 5
239000000843 powder Substances 0.000 claims description 5
229960002663 thioctic acid Drugs 0.000 claims description 5
AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 4
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 4
CCTREOMTIFSZAU-OGFXRTJISA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;5-[(3r)-dithiolan-3-yl]pentanoic acid Chemical compound OCC(N)(CO)CO.OC(=O)CCCC[C@@H]1CCSS1 CCTREOMTIFSZAU-OGFXRTJISA-N 0.000 claims description 4
JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 claims description 4
AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 4
230000003556 anti-epileptic effect Effects 0.000 claims description 4
239000001961 anticonvulsive agent Substances 0.000 claims description 4
229960003965 antiepileptics Drugs 0.000 claims description 4
230000015572 biosynthetic process Effects 0.000 claims description 4
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 4
229960003667 flupirtine Drugs 0.000 claims description 4
235000019136 lipoic acid Nutrition 0.000 claims description 4
239000011159 matrix material Substances 0.000 claims description 4
238000012986 modification Methods 0.000 claims description 4
230000004048 modification Effects 0.000 claims description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 4
239000003826 tablet Substances 0.000 claims description 4
229960004380 tramadol Drugs 0.000 claims description 4
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 4
RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 claims description 4
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 3
UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 claims description 3
229960001066 disopyramide Drugs 0.000 claims description 3
239000008298 dragée Substances 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
DSFGXPJYDCSWTA-UHFFFAOYSA-N 7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(O)CN(CCO)C DSFGXPJYDCSWTA-UHFFFAOYSA-N 0.000 claims description 2
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 2
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 2
239000002269 analeptic agent Substances 0.000 claims description 2
230000003555 analeptic effect Effects 0.000 claims description 2
229940035676 analgesics Drugs 0.000 claims description 2
239000000730 antalgic agent Substances 0.000 claims description 2
230000003266 anti-allergic effect Effects 0.000 claims description 2
230000001088 anti-asthma Effects 0.000 claims description 2
230000003178 anti-diabetic effect Effects 0.000 claims description 2
230000003474 anti-emetic effect Effects 0.000 claims description 2
239000000043 antiallergic agent Substances 0.000 claims description 2
239000003416 antiarrhythmic agent Substances 0.000 claims description 2
239000000924 antiasthmatic agent Substances 0.000 claims description 2
239000002111 antiemetic agent Substances 0.000 claims description 2
229940125683 antiemetic agent Drugs 0.000 claims description 2
239000002282 antimigraine agent Substances 0.000 claims description 2
229940125684 antimigraine agent Drugs 0.000 claims description 2
239000003435 antirheumatic agent Substances 0.000 claims description 2
BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 2
229960000911 benserazide Drugs 0.000 claims description 2
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims description 2
229960000516 bezafibrate Drugs 0.000 claims description 2
230000001813 broncholytic effect Effects 0.000 claims description 2
229960001948 caffeine Drugs 0.000 claims description 2
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 2
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 2
WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 claims description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
229960001259 diclofenac Drugs 0.000 claims description 2
HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims description 2
229960004704 dihydroergotamine Drugs 0.000 claims description 2
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 2
229960004166 diltiazem Drugs 0.000 claims description 2
229960004993 dimenhydrinate Drugs 0.000 claims description 2
MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 claims description 2
239000002934 diuretic Substances 0.000 claims description 2
229940030606 diuretics Drugs 0.000 claims description 2
RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 claims description 2
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 2
229960002297 fenofibrate Drugs 0.000 claims description 2
239000000945 filler Substances 0.000 claims description 2
229960004580 glibenclamide Drugs 0.000 claims description 2
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 2
230000000055 hyoplipidemic effect Effects 0.000 claims description 2
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 2
229960000201 isosorbide dinitrate Drugs 0.000 claims description 2
229960004502 levodopa Drugs 0.000 claims description 2
XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 claims description 2
XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 2
229910052808 lithium carbonate Inorganic materials 0.000 claims description 2
229960005181 morphine Drugs 0.000 claims description 2
229940035363 muscle relaxants Drugs 0.000 claims description 2
239000003158 myorelaxant agent Substances 0.000 claims description 2
229920000728 polyester Polymers 0.000 claims description 2
239000011148 porous material Substances 0.000 claims description 2
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 2
229960003908 pseudoephedrine Drugs 0.000 claims description 2
229960001404 quinidine Drugs 0.000 claims description 2
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 2
229960003708 sumatriptan Drugs 0.000 claims description 2
229960001402 tilidine Drugs 0.000 claims description 2
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 2
229960000604 valproic acid Drugs 0.000 claims description 2
229960002726 vincamine Drugs 0.000 claims description 2
229940118318 xanthinol Drugs 0.000 claims description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 1
KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 claims 1
MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 1
YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 claims 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims 1
GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 claims 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
229960005119 amitriptyline hydrochloride Drugs 0.000 claims 1
230000002205 anti-dementic effect Effects 0.000 claims 1
229940125688 antiparkinson agent Drugs 0.000 claims 1
229960004574 azelastine Drugs 0.000 claims 1
229960004205 carbidopa Drugs 0.000 claims 1
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 1
239000007884 disintegrant Substances 0.000 claims 1
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims 1
229960001389 doxazosin Drugs 0.000 claims 1
229960002490 fosinopril Drugs 0.000 claims 1
239000001087 glyceryl triacetate Substances 0.000 claims 1
235000013773 glyceryl triacetate Nutrition 0.000 claims 1
239000003326 hypnotic agent Substances 0.000 claims 1
230000000147 hypnotic effect Effects 0.000 claims 1
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims 1
229960003827 isosorbide mononitrate Drugs 0.000 claims 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims 1
229960002237 metoprolol Drugs 0.000 claims 1
XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 claims 1
229960004027 molsidomine Drugs 0.000 claims 1
229960003642 nicergoline Drugs 0.000 claims 1
229960004526 piracetam Drugs 0.000 claims 1
229940125723 sedative agent Drugs 0.000 claims 1
239000000932 sedative agent Substances 0.000 claims 1
229910021653 sulphate ion Inorganic materials 0.000 claims 1
MXFWWQICDIZSOA-UHFFFAOYSA-N talinolol Chemical compound C1=CC(OCC(O)CNC(C)(C)C)=CC=C1NC(=O)NC1CCCCC1 MXFWWQICDIZSOA-UHFFFAOYSA-N 0.000 claims 1
229960003658 talinolol Drugs 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 claims 1
NZFNXWQNBYZDAQ-UHFFFAOYSA-N thioridazine hydrochloride Chemical compound Cl.C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C NZFNXWQNBYZDAQ-UHFFFAOYSA-N 0.000 claims 1
229960004098 thioridazine hydrochloride Drugs 0.000 claims 1
229960002622 triacetin Drugs 0.000 claims 1
WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims 1
229960001722 verapamil Drugs 0.000 claims 1
238000005469 granulation Methods 0.000 abstract description 24
230000003179 granulation Effects 0.000 abstract description 24
238000009472 formulation Methods 0.000 abstract description 9
239000003814 drug Substances 0.000 abstract description 6
230000003111 delayed effect Effects 0.000 abstract description 5
230000000694 effects Effects 0.000 abstract description 4
230000004927 fusion Effects 0.000 abstract 2
SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 55
238000011156 evaluation Methods 0.000 description 20
150000004665 fatty acids Chemical class 0.000 description 9
239000002245 particle Substances 0.000 description 7
239000007787 solid Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
230000008901 benefit Effects 0.000 description 6
238000009792 diffusion process Methods 0.000 description 6
150000002148 esters Chemical class 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000000155 melt Substances 0.000 description 5
238000002156 mixing Methods 0.000 description 5
239000008213 purified water Substances 0.000 description 5
229940116224 behenate Drugs 0.000 description 4
UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 4
238000001816 cooling Methods 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
239000003925 fat Substances 0.000 description 4
239000012530 fluid Substances 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
239000012071 phase Substances 0.000 description 4
229920002785 Croscarmellose sodium Polymers 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
229960001681 croscarmellose sodium Drugs 0.000 description 3
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
235000019700 dicalcium phosphate Nutrition 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
230000003628 erosive effect Effects 0.000 description 3
235000011389 fruit/vegetable juice Nutrition 0.000 description 3
239000003906 humectant Substances 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
239000008183 oral pharmaceutical preparation Substances 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 2
DPYIXBFZUMCMJM-BTJKTKAUSA-N (z)-but-2-enedioic acid;ethyl n-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate Chemical compound OC(=O)\C=C/C(O)=O.N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 DPYIXBFZUMCMJM-BTJKTKAUSA-N 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 2
GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 2
ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
239000011324 bead Substances 0.000 description 2
235000013339 cereals Nutrition 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
238000009509 drug development Methods 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 2
229960001655 flupirtine maleate Drugs 0.000 description 2
239000000416 hydrocolloid Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000035515 penetration Effects 0.000 description 2
MRWQRJMESRRJJB-UHFFFAOYSA-N pentifylline Chemical compound O=C1N(CCCCCC)C(=O)N(C)C2=C1N(C)C=N2 MRWQRJMESRRJJB-UHFFFAOYSA-N 0.000 description 2
ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
229920000058 polyacrylate Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000003340 retarding agent Substances 0.000 description 2
230000000979 retarding effect Effects 0.000 description 2
150000004671 saturated fatty acids Chemical class 0.000 description 2
235000003441 saturated fatty acids Nutrition 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
150000003445 sucroses Chemical class 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
229960003107 tramadol hydrochloride Drugs 0.000 description 2
150000004670 unsaturated fatty acids Chemical class 0.000 description 2
235000021122 unsaturated fatty acids Nutrition 0.000 description 2
239000001993 wax Substances 0.000 description 2
IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
101100235626 Caenorhabditis elegans hlb-1 gene Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
229940035678 anti-parkinson drug Drugs 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
208000018300 basal ganglia disease Diseases 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229940112822 chewing gum Drugs 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
229940071160 cocoate Drugs 0.000 description 1
235000020186 condensed milk Nutrition 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
238000007499 fusion processing Methods 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
101150028517 hlb gene Proteins 0.000 description 1
238000009474 hot melt extrusion Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000005555 hypertensive agent Substances 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960004815 meprobamate Drugs 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
238000003801 milling Methods 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000008385 outer phase Substances 0.000 description 1
239000003973 paint Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229960002371 pentifylline Drugs 0.000 description 1
229960000969 phenyl salicylate Drugs 0.000 description 1
229910001392 phosphorus oxide Inorganic materials 0.000 description 1
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical class [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229960001085 piretanide Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000007670 refining Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
229940066675 ricinoleate Drugs 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229940084026 sodium valproate Drugs 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960002784 thioridazine Drugs 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Biophysics (AREA)

SK1325-2002A 2000-03-08 2001-03-06 Farmaceutické prípravky SK13252002A3 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE2000110509 DE10010509A1 (de)	2000-03-08	2000-03-08	Pharmazeutische Formulierungen
US18796200P	2000-03-09	2000-03-09
PCT/EP2001/002500 WO2001066081A2 (fr)	2000-03-08	2001-03-06	Formulations pharmaceutiques

Publications (1)

Publication Number	Publication Date
SK13252002A3 true SK13252002A3 (sk)	2003-07-01

Family

ID=26004678

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1325-2002A SK13252002A3 (sk)	2000-03-08	2001-03-06	Farmaceutické prípravky

Country Status (22)

Country	Link
EP (1)	EP1267828B1 (fr)
JP (1)	JP2003528829A (fr)
KR (1)	KR20020083171A (fr)
CN (1)	CN1212831C (fr)
AT (1)	ATE334659T1 (fr)
AU (1)	AU2001250365A1 (fr)
BG (1)	BG107064A (fr)
BR (1)	BR0109036A (fr)
CA (1)	CA2339913C (fr)
CZ (1)	CZ20023009A3 (fr)
DE (1)	DE50110617D1 (fr)
EA (1)	EA200200951A1 (fr)
EE (1)	EE200200504A (fr)
GE (1)	GEP20053455B (fr)
HR (1)	HRP20020804B1 (fr)
HU (1)	HUP0204513A3 (fr)
IS (1)	IS6511A (fr)
NO (1)	NO20024237L (fr)
NZ (1)	NZ521215A (fr)
PL (1)	PL202935B1 (fr)
SK (1)	SK13252002A3 (fr)
WO (1)	WO2001066081A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003209475A1 (en) *	2002-03-07	2003-09-16	Vectura Limited	Fast melt multiparticulate formulations for oral delivery
EP1585501A4 (fr) *	2003-01-23	2007-04-25	Amorepacific Corp	Preparations a liberation prolongee et procede de production de ces preparations
DE10341264A1 (de) *	2003-09-04	2005-03-24	Grünenthal GmbH	Schmelzformulierte, multipartikuläre orale Darreichungsform
WO2005101979A2 (fr) *	2004-04-22	2005-11-03	Mor Research Applications Ltd.	Methode de gestion de la prise d'aliments
AU2009270768A1 (en) *	2008-07-18	2010-01-21	Valeant Pharmaceuticals International	Modified release formulation and methods of use
US8715715B2 (en) *	2008-11-03	2014-05-06	Nal Pharmaceuticals Ltd.	Dosage form for insertion into the mouth
DE102009013612A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
DE102009013611A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Festes Retigabin in nicht-kristalliner Form
DE102009013613A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Trockenverarbeitung von Retigabin
EA201290663A1 (ru) *	2010-01-20	2013-03-29	Вэлиант Фармасьютикалс Интернешнл	Состав с модифицированным высвобождением и способы применения
WO2013004249A1 (fr)	2011-07-05	2013-01-10	Concit Pharma Aps	Utilisation d'agonistes de récepteur de sérotonine pour le traitement de troubles des mouvements
ES2616887T3 (es) *	2013-10-29	2017-06-14	Echo Pharmaceuticals B.V.	Comprimido que contiene delta 9-tetrahidrocannabinol, método para su producción y uso de tal comprimido en el tratamiento oral
AU2017361129B2 (en) *	2016-11-18	2023-11-09	The Kids Research Institute Australia	Taste masking product
CN107441055A (zh) *	2017-08-03	2017-12-08	山东则正医药技术有限公司	一种控释药物的制备方法
CN108853044B (zh) *	2018-07-06	2020-11-06	郑州明泽医药科技有限公司	一种硝苯地平缓释片及其制备方法
CN109679147B (zh) *	2018-12-28	2021-05-11	广西科技师范学院	植物微细纤维蔗糖脂肪酸酯富集物及制备方法
GB201904767D0 (en)	2019-04-04	2019-05-22	Orexo Ab	New pharmaceutical compositions
WO2021145625A1 (fr) *	2020-01-13	2021-07-22	한국유나이티드제약 주식회사	Composition pharmaceutique comprenant de l'acide r-thioctique ou son sel pharmaceutiquement acceptable et substance de base d'enrobage entérique
CN111513192A (zh) *	2020-05-19	2020-08-11	北京中联华康科技有限公司	一种酯化半胱胺盐酸盐稳定型粉末及其制备方法与应用
CN114983964B (zh) *	2022-06-24	2024-05-03	广东恒健制药有限公司	一种头孢地尼颗粒剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS63101320A (ja) *	1986-10-17	1988-05-06	Dainippon Pharmaceut Co Ltd	バルプロ酸カルシウム製剤
JPH07267850A (ja) *	1994-03-28	1995-10-17	Eisai Co Ltd	不快味を防止した医薬組成物及びその製造方法
JP4078567B2 (ja) *	1997-04-25	2008-04-23	東和薬品株式会社	徐放性マイクロカプセル及びその製法
JP4299384B2 (ja) *	1997-07-15	2009-07-22	富山化学工業株式会社	溶出遅延防止細粒剤
PT2198858E (pt) *	1998-03-26	2011-09-01	Astellas Pharma Inc	Composição farmacêutica de libertação constante que contém um macrólido como o tacrolimus
DE19840152A1 (de) *	1998-09-03	2000-03-09	Dresden Arzneimittel	Calciumvalproat enthaltende pharmazeutische Zusammensetzungen mit retardierter Wirkstoff-Freisetzung, Verfahren zu deren Herstellung und deren Verwendung
DE19916383A1 (de) *	1999-03-31	2000-10-05	Schering Ag	Pharmazeutische Zusammensetzung mit einem Extrusionsstoff

2001
- 2001-03-06 HU HU0204513A patent/HUP0204513A3/hu unknown
- 2001-03-06 WO PCT/EP2001/002500 patent/WO2001066081A2/fr not_active Ceased
- 2001-03-06 AT AT01923641T patent/ATE334659T1/de not_active IP Right Cessation
- 2001-03-06 HR HR20020804A patent/HRP20020804B1/xx not_active IP Right Cessation
- 2001-03-06 PL PL362547A patent/PL202935B1/pl not_active IP Right Cessation
- 2001-03-06 CZ CZ20023009A patent/CZ20023009A3/cs unknown
- 2001-03-06 NZ NZ521215A patent/NZ521215A/en unknown
- 2001-03-06 EP EP01923641A patent/EP1267828B1/fr not_active Revoked
- 2001-03-06 CN CNB018061893A patent/CN1212831C/zh not_active Expired - Fee Related
- 2001-03-06 DE DE50110617T patent/DE50110617D1/de not_active Revoked
- 2001-03-06 AU AU2001250365A patent/AU2001250365A1/en not_active Abandoned
- 2001-03-06 KR KR1020027011672A patent/KR20020083171A/ko not_active Ceased
- 2001-03-06 SK SK1325-2002A patent/SK13252002A3/sk not_active Application Discontinuation
- 2001-03-06 EE EEP200200504A patent/EE200200504A/xx unknown
- 2001-03-06 JP JP2001564734A patent/JP2003528829A/ja active Pending
- 2001-03-06 EA EA200200951A patent/EA200200951A1/ru unknown
- 2001-03-06 BR BR0109036-4A patent/BR0109036A/pt not_active Application Discontinuation
- 2001-03-06 GE GE4946A patent/GEP20053455B/en unknown
- 2001-03-07 CA CA002339913A patent/CA2339913C/fr not_active Expired - Fee Related
2002
- 2002-08-20 IS IS6511A patent/IS6511A/is unknown
- 2002-09-05 BG BG107064A patent/BG107064A/bg unknown
- 2002-09-05 NO NO20024237A patent/NO20024237L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2001250365A1 (en)	2001-09-17
GEP20053455B (en)	2005-02-25
PL202935B1 (pl)	2009-08-31
CZ20023009A3 (cs)	2003-06-18
DE50110617D1 (de)	2006-09-14
CA2339913C (fr)	2009-02-24
KR20020083171A (ko)	2002-11-01
NO20024237D0 (no)	2002-09-05
JP2003528829A (ja)	2003-09-30
WO2001066081A3 (fr)	2002-03-14
EA200200951A1 (ru)	2003-02-27
EP1267828B1 (fr)	2006-08-02
HUP0204513A2 (en)	2003-05-28
NZ521215A (en)	2005-04-29
HRP20020804B1 (en)	2008-06-30
ATE334659T1 (de)	2006-08-15
PL362547A1 (en)	2004-11-02
CN1418091A (zh)	2003-05-14
CN1212831C (zh)	2005-08-03
HRP20020804A2 (en)	2004-12-31
EP1267828A2 (fr)	2003-01-02
CA2339913A1 (fr)	2001-09-08
HK1054697A1 (en)	2003-12-12
BG107064A (bg)	2003-04-30
HUP0204513A3 (en)	2004-06-28
BR0109036A (pt)	2003-03-18
IS6511A (is)	2002-08-20
EE200200504A (et)	2004-02-16
WO2001066081A2 (fr)	2001-09-13
NO20024237L (no)	2002-09-05

Legal Events

Date	Code	Title	Description
2010-05-07	FC9A	Refused patent application

Publication	Publication Date	Title
US20020015730A1 (en)	2002-02-07	Pharmaceutical formulations and method for making
CZ20023009A3 (cs)	2003-06-18	Farmaceutické přípravky
US6953593B2 (en)	2005-10-11	Sustained-release microencapsulated delivery system
JP3261707B2 (ja)	2002-03-04	ペレットの製造法
CA2132451C (fr)	2003-06-10	Procede de preparation de comprimes a degagement prolonge
AU623177B2 (en)	1992-05-07	Granular pharmaceutical formulations
AU2002351850B2 (en)	2008-01-24	Solid, stabilized, prompt-and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs
EP2136792B1 (fr)	2012-12-26	Micropellets thermofusibles
JP2003528829A6 (ja)	2004-07-08	薬剤学的製剤
US20040121003A1 (en)	2004-06-24	Methods for making pharmaceutical formulations comprising deagglomerated microparticles
AU2002351850A1 (en)	2003-07-24	Solid, stabilized, prompt-and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs
KR101613775B1 (ko)	2016-04-19	수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR20100087011A (ko)	2010-08-02	매트릭스형 의약 고형 제제
CN101919822B (zh)	2013-10-23	综合性能改善的片剂及其制备方法
KR100844628B1 (ko)	2008-07-07	제약상 다입자의 제조 방법
Paradkar et al.	2010	Crystallo-co-agglomeration: A novel particle engineering technique
CZ303694B6 (cs)	2013-03-20	Prípravek nesteroidního protizánetlivého léciva obsahující granulární a extragranulární kompozici a zpusob jeho prípravy
US20110294864A1 (en)	2011-12-01	Aqueous coacervate compositions suitable for making powders and water-soluble formulations of biologically-active agents
LT5033B (lt)	2003-07-25	Kontroliuojamo išsiskyrimo farmacinė kompozicija, turinti tramadolo hidrochlorido, ir jos paruošimo būdas
WO2010081815A1 (fr)	2010-07-22	Compositions aqueuses coacervées comprenant des agents biologiquement actifs faiblement solubles dans l'eau
ZA200207050B (en)	2002-11-20	Pharmaceutical preparations.
Jain et al.	0	Role of lipid excipients in oral sustained release drug delivery systems
EP2407156A2 (fr)	2012-01-18	Compositions coacervatées aqueuses adaptées à la fabrication de poudres et formulations solubles dans l'eau d'agents actifs biologiques
SK15612000A3 (sk)	2002-05-09	Perorálne tablety s riadeným uvoľňovaním farmaceuticky akceptovateľných solí metoprololu a spôsob ich prípravy